Project title: Exploiting the power of human induced pluripotent stem cell extracellular vesicles as a new anti- inflammatory drug for lung ischemia reperfusion injury
Start/end date: May 2023 – June 2025
Funding Agency/Programme: National Recovery and Resilience Plan (NRRP) – Mission 6 (Health), Component 2 – Investment 2.1. Enhancement and strengthening of NHS biomedical research. (Proof Of Concept).
Partnership: Fondazione Cá Granda – Ospedale Maggiore Policlinico (Applicant); Fondazione Ri.MED (Partner); ISMETT IRCCS (Partner).
Abstract: The project aims to assess the technical and commercial feasibility of an innovative cell-free nanomedicine strategy based on extracellular vesicles (EV), human induced pluripotent stem cells, and a young cell source such as cord blood for the treatment of lung ischemia reperfusion injury. The project is focused on a patent which highlights the strong anti-inflammatory role of EV isolated from cord blood mesenchymal stromal induced pluripotent stem cells.
Ri.MED U.O.: Tissue Engineering Lab.
Ri.MED Principal Investigator: Antonio D’Amore
Ri.MED Leading Scientist: Federica Cosentino
